Armata Pharmaceuticals Announces Structural Biology Publication
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2024
0mins
Source: PRnewswire
Phage Structure Research: Armata Pharmaceuticals announced a publication detailing the structure of phage Pa193, which is part of their multi-phage clinical candidate aimed at treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients.
Advancements in Phage Therapy: The study enhances understanding of phage biology and structural components, potentially expanding the use of phages as therapeutics for various dangerous pathogens beyond P. aeruginosa.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
